AstraZeneca said on Thursday its drug Lynparza, developed with U.S.-based Merck & Co, was approved by the European Union as an adjuvant treatment for patients with a form of a genetically mutated early-stage breast cancer.
AstraZeneca drug Lynparza, developed with U.S.-based Merck & Co, was approved by the European Union as an adjuvant treatment for patients with a form of a genetically mutated early-stage breast cancer.
